Early immunomodulation in immune thrombocytopenia—A report of the ICIS meeting in Lenzerheide, Switzerland 2022
British Journal of Haematology · 2023
DOI: 10.1111/bjh.19082 ↗At a glance
Übersichtsarbeit in British Journal of Haematology, 2023. Written by Tomás José González-López and 1 co-authors. Institution: Department of Haematology, Hospital Universitario de Burgos, Burgos, Spain. Major MEDLINE topics: Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia. Cited 1 times so far (Crossref); 105 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
The only way to prevent immune thrombocytopenia (ITP) from becoming refractory would be to restore tolerance to platelets at an early phase of the disease. Numerous immune alterations probably accumulate in chronic ITP; thus, the chances of cure decrease significantly with time. Currently, sustained remission off treatment (SROT) is a clinical definition describing patients who can discontinue their ITP treatment without risk and maintain a state of remission. Different treatment strategies are presently being evaluated with the goal of attaining SROT, mostly combining drugs targeting the innate and/or the adaptive immune system, the inflammation state, so as increasing the platelet load. In this sense, thrombopoietin receptor agonists (TPO‐RAs) have shown promising results if used as upfront treatment. TPO‐RAs seem to exhibit immunomodulation and immune tolerance properties, increasing not only the platelet antigen mass but also increasing the transforming growth factor‐β concentration, and stimulating regulatory T and B lymphocytes. However, more immunological studies are needed to establish accurate molecular alterations in ITP that are potentially reversed with treatments.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Haematology, Hospital Universitario de Burgos, Burgos, Spain.
- Department of Haematology/Oncology, University Children's Hospital Basel, Basel, Switzerland.
ORCID profiles: Tomás José González-López, Alexandra Schifferli
Cite
APA
González-López, T. J., & Schifferli, A. (2023). Early immunomodulation in immune thrombocytopenia—A report of the ICIS meeting in Lenzerheide, Switzerland 2022. British Journal of Haematology. https://doi.org/10.1111/bjh.19082
Vancouver
González-López TJ, Schifferli A. Early immunomodulation in immune thrombocytopenia—A report of the ICIS meeting in Lenzerheide, Switzerland 2022. British Journal of Haematology. 2023. doi:10.1111/bjh.19082
BibTeX
@article{GonzlezLpez2023,
author = {González-López, Tomás José and Schifferli, Alexandra},
title = {Early immunomodulation in immune thrombocytopenia—A report of the ICIS meeting in Lenzerheide, Switzerland 2022},
journal = {British Journal of Haematology},
year = {2023},
doi = {10.1111/bjh.19082}
}
EUVIMED